ATXS News and Press, Astria Therapeutics Inc. From 07/20/23

-- On Track for Proof-of-Concept Results in HAE Patients in Mid-2024 -- -- Results To-Date Support STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named John Ruesch as Senior Vice ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding pa...

2023-07-07 18:04:08 ET Summary Astria Therapeutics is developing STAR-0215, a monoclonal antibody inhibitor, for the treatment of hereditary angioedema (HAE), with promising initial findings and ongoing clinical trials. The company reported a Q1 2023 operating loss of $13.5 millio...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and i...

2023-05-11 17:19:12 ET Astria TherapeuticS press release ( NASDAQ: ATXS ): Q1 GAAP EPS of -$0.40 beats by $0.15 . As of March 31, 2023, Astria had cash, cash equivalents and short-term investments of $213.3 million, compared to $226.4 million as of December 31, 2022. T...

-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial -- -- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Ro...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and i...

2023-04-24 08:10:36 ET Summary Proof of concept in using STAR-0215 as a preventative Hereditary Angioedema therapy had been established. Results from the phase 1b/2 ALPHA-STAR study using STAR-0215 as a preventative therapy for HAE are going to be released in mid-2024. It is e...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief...